Literature DB >> 12574203

Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state.

Päivi Härkönen1, Svea Törn, Riitta Kurkela, Katja Porvari, Anitta Pulkka, Aija Lindfors, Veli Isomaa, Pirkko Vihko.   

Abstract

The progression of prostate cancer during androgen deprivation therapy is a serious clinical problem. Little is known, however, about the mechanisms behind the transition of the disease to an androgen-independent stage. In the present report, we provide evidence of substantial changes in both estrogen and androgen metabolism during the transition of cultured prostate cancer LNCaP (lymph node carcinoma of the prostate) cells. The results of enzyme activity measurements performed using HPLC suggest that, related to the transition, there exists a remarkable decrease in the oxidative 17 beta-hydroxysteroid dehydrogenase (17HSD) activity, whereas the reductive 17HSD activity seems to increase. Relative quantitative RT-PCR revealed that the decrease in oxidative activity largely coincided with the remarkable decrease in the expression of the HSD17B2 gene. Furthermore, the present data suggest that the observed increasing activity of 17HSD type 7 could lead to the increased intracellular production of 17 beta-estradiol during disease progression. This was supported by the cDNA microarray screening results, which showed a considerable overexpression of several estrogen up-regulated genes in the LNCaP cell line variant that represents progressive prostate cancer. Because 17HSDs critically contribute to the control of bioavailability of active sex steroid hormones locally in the prostate, the observed variation in intraprostatic 17HSD activity might be predicted to be crucially involved in the regulation of growth and function of the organ.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574203     DOI: 10.1210/jc.2002-020236

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Serum follistatin in patients with prostate cancer metastatic to the bone.

Authors:  Francesca Maria Tumminello; Giuseppe Badalamenti; Fabio Fulfaro; Lorena Incorvaia; Marilena Crescimanno; Carla Flandina; Maria Vittoria Sepporta; Gaetano Leto
Journal:  Clin Exp Metastasis       Date:  2010-07-11       Impact factor: 5.150

2.  Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers.

Authors:  Joseph E Ippolito; Matthew E Merritt; Fredrik Bäckhed; Krista L Moulder; Steven Mennerick; Jill K Manchester; Seth T Gammon; David Piwnica-Worms; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

3.  Role of sex hormones in the modulation of cholangiocyte function.

Authors:  Romina Mancinelli; Paolo Onori; Sharon Demorrow; Heather Francis; Shannon Glaser; Antonio Franchitto; Guido Carpino; Gianfranco Alpini; Eugenio Gaudio
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

4.  Tissue-specific transcription profiles of sex steroid biosynthesis enzymes and the androgen receptor.

Authors:  U Hoppe; P-M Holterhus; L Wünsch; D Jocham; T Drechsler; S Thiele; C Marschke; O Hiort
Journal:  J Mol Med (Berl)       Date:  2006-03-25       Impact factor: 4.599

Review 5.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

Review 6.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

7.  Peroxisome proliferator-activated receptor gamma down-regulates follistatin in intestinal epithelial cells through SP1.

Authors:  Brian M Necela; Weidong Su; E Aubrey Thompson
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

8.  Molecular genetic evidence for different clonal origins of epithelial and stromal components of phyllodes tumor of the prostate.

Authors:  Ryan P McCarthy; Shaobo Zhang; David G Bostwick; Junqi Qian; John N Eble; Mingsheng Wang; Haiqun Lin; Liang Cheng
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

9.  Sex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinology.

Authors:  Daniele Gianfrilli; Silvia Pierotti; Riccardo Pofi; Costantino Leonardo; Mauro Ciccariello; Federica Barbagallo
Journal:  Biomed Res Int       Date:  2014-08-13       Impact factor: 3.411

10.  A Testosterone Metabolite 19-Hydroxyandrostenedione Induces Neuroendocrine Trans-Differentiation of Prostate Cancer Cells via an Ectopic Olfactory Receptor.

Authors:  Tatjana Abaffy; James R Bain; Michael J Muehlbauer; Ivan Spasojevic; Shweta Lodha; Elisa Bruguera; Sara K O'Neal; So Young Kim; Hiroaki Matsunami
Journal:  Front Oncol       Date:  2018-05-28       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.